Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study

Journal of Clinical Oncology

Volumn 23, Issue 24, 2005, Pages 5464-5473

  Liu, Glenn ^a   Rugo, Hope S ^a   Wilding, George ^a   McShane, Teresa M ^a   Evelhoch, Jeffrey L ^a   Ng, Chaan ^a   Jackson, Edward ^a   Kelcz, Frederick ^a   Yeh, Benjamin M ^a   Lee Jr , Fred T ^a   Charnsangavej, Chusilp ^a   Park, John W ^a   Ashton, Edward A ^a   Steinfeldt, Heidi M ^a   Pithavala, Yazdi K ^a   Reich, Steven D ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; MERKEL CELL TUMOR; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN CANCER; SOLID TUMOR; STOMATITIS; THYROID CANCER; BLOOD; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); ORAL DRUG ADMINISTRATION; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; AREA UNDER CURVE; CONTRAST MEDIA; DRUG ADMINISTRATION SCHEDULE; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 24944515034     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.143     Document Type: Article

References (33)

1. Pfizer Global Research and Development: AG-013736: Investigator's Brochure. Pfizer Global Research and Development, La Jolla, CA, 2004
2. DeGruttola VG, Clax P, DeMEts DL, et al: Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop. Controlled Clin Trials 22:485-502, 2001
3. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
4. Ellis LM: Antiangiogenic therapy at a crossroads: Clinical trial results and future directions. J Clin Oncol 21:281-283, 2003
5. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
6. Thomas JP, Arzoomanian RZ, Alberti D, et al: Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223-231, 2003
7. Herbst RS, Mullani NA, Davis DW, et al: Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-3814, 2002
8. Yuh WT: An exciting and challenging role for advanced contrast MR imaging. J Magn Reson Imaging 10:221-222, 1999
9. Taylor JS, Tofts PS, Port R, et al: MR imaging of tumors microcirculation: Promise for a new millennium. J Magn Reson Imaging 10:260-266, 1999
10. Padhani AR: Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions. J Magn Reson Imaging 16:407-422, 2002
11. Knopp MV, Brix G, Junkermann HJ, et al: MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am 2:633-658, 1994
12. Barentsz JO, Berger-Hartog O, Witjes JA, et al: Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791-797, 1998
13. Reddick WE, Taylor JS, Fletcher BD: Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 10:277-285, 1999
14. De Vries A, Griebel J, Kremser C, et al: Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: Preliminary results and implications for therapy. Radiology 217:385-391, 2000
15. Mayr NA, Yuh WT, Arnholt JC, et al: Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12:1027-1033, 2000
16. Padhani AR, MacVicar AD, Gapskinski CJ, et al: Effects of androgen deprivation on prostatatic morphology and vascular permeability evaluated with MR imaging. Radiology 218:365-374, 2001
17. Checkley D, Tessier JJ, Kendrew J, et al: Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signaling inhibitor, in PC-3 prostate tumors. Br J Cancer 89:1889-1895, 2003
18. Brasch R, Pham C, Shames D, et al: Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 7:68-74, 1997
19. Wilmes LJ, Hylton N, Wang DH, et al: AG-013736, a novel VEGFR TK inhibitor, suppresses tumor growth and vascular permeability in human BT474 breast cancer xenografts in nude mice. Proc Am Assoc Cancer Res 44:863, 2003 (abstr 3772)
20. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of vascular endothelial growth factor receptor tyrosme kinases, in patients with advanced colorectal cancer and liver metastasis: Results from two phase I trials. J Clin Oncol 21:3955-3964, 2003
21. Stevenson JP, Rosen M, Sun W, et al: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered blood flow. J Clin Oncol 21:4428-4438, 2003
22. Evelhoch JL, LoRusso PM, He Z, et al: Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10:3650-3657, 2004
23. Galbraith SM, Rustin G, Lodge MA, et al: Effects of 5,6- dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826-3840, 2002
24. Ashton EA, Takahashi C, Berg MJ, et al: Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRI. J Magn Reson Imaging 17:300-308, 2003
25. Tofts PS, Brix G, Buckley DL, et al: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10:223-232, 1999
26. Mattiello J, Evelhoch JL: Relative volume-average murine tumor blood flow measurement via deuterium nuclear magnetic resonance spectroscopy. Magn Reson Med 18:320-334, 1991
27. Rugo HS, Herbst RS, Liu G, et al: Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. J Clin Oncol 23:10.1200/JCO.2005.04.192
28. Willett CG, Boucher Y, di Tomasso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
29. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
30. Galbraith SM, Lodge MA, Taylor NJ, et al: Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis. NMR Biomed 15:132-142, 2002
31. Padhani AR, Husband JE: Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 56:607-620, 2001
32. Rijpkema M, Kaanders J, Joosten F, et al: Method for qualitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 14:457-463, 2001
33. Collins JM: Functional imaging in phase I studies: Decorations or decision making? J Clin Oncol 21:2807-2809, 2003